Adaptimmune Therapeutics PLC ADR | Key People and Executives
James Julian Noble
Chief Executive Officer & Executive Director
John Furey
Independent Non-Executive Director
Ali Behbahani
Independent Non-Executive Director
Tal Zaks
Independent Non-Executive Director
Giles Francis Bertram Kerr
Independent Non-Executive Director
Barbara Gayle Duncan
Independent Non-Executive Director
Charles Elliott Sigal
Independent Non-Executive Director
Lawrence M. Alleva
Independent Non-Executive Director
James Julian Noble
Chief Executive Officer & Executive Director
William C. Bertrand
Chief Operating Officer
Adrian Rawcliffe
CFO & Principal Accounting Officer
Gwendolyn Binder-Scholl
Chief Technology Officer
Rafael Amado
Chief Medical Officer
Paul Stead
Vice President-Business Development
Helena Katrina Tayton-Martin
Chief Business Officer
Michael Blackton
Vice President-Quality Assurance
Sãbastien Desprez
Vice President-Communications & Investor Relations
Margaret Henry
Secretary & Head-Public Relations
John Furey
Independent Non-Executive Director
Ali Behbahani
Independent Non-Executive Director
Tal Zaks
Independent Non-Executive Director
Giles Francis Bertram Kerr
Independent Non-Executive Director
Barbara Gayle Duncan
Independent Non-Executive Director
Charles Elliott Sigal
Independent Non-Executive Director
Lawrence M. Alleva
Independent Non-Executive Director
| Address |
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
|
|
Employees
|
- |
| Website |
http://adaptimmune.com |
| Updated |
07/08/2019 |
| Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. |
